Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Angiogenesis, Metastasis, and the Cellular Microenvironment

Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma

Julia L. Zhong, Zaruhi Poghosyan, Caroline J. Pennington, Xanthe Scott, Madeleine M. Handsley, Alba Warn, Jelena Gavrilovic, Katja Honert, Achim Krüger, Paul N. Span, Fred C.G.J. Sweep and Dylan R. Edwards
Julia L. Zhong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaruhi Poghosyan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline J. Pennington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xanthe Scott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madeleine M. Handsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alba Warn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jelena Gavrilovic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Honert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Achim Krüger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Span
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred C.G.J. Sweep
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dylan R. Edwards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-07-2028 Published March 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Domain organization of ADAM-15 and the sequence differences of the splice variants. A. Schematic of the exon organization of the portion of ADAM15 encompassing the cytoplasmic domain. Exons are shown as numbered black boxes. Exon 20a and 20b differ by one amino acid due to the presence of a tandem NAGNAG splice acceptor sequence (29); exons 21a and 21b differ in their use of the 3′ splice site, as shown by a gray box for the longer exon 21b (29). B. Schematic representation of the cytoplasmic domains of the ADAM-15A, ADAM-15B, ADAM-15C, and ADAM-15D variants, and the exons from which they are derived. PXXP motifs are underlined. Class I (RXXPXXP) and class II (PXXPXR) ligands for Src family PTK are in boldface type. The National Center for Biotechnology Information protein database entries for these proteins are as follows: ADAM-15A (the original ADAM-15): NP_003806 (814 amino acids); ADAM-15B: NP_997077, with a 75-bp insert, contains one additional proline-rich insert (italic); ADAM-15C: NP_997080, with an additional 72-bp insert, contains an additional proline-rich insert (italic with a line below); ADAM-15D: NP_997074, the shortest ADAM-15, which introduces a frameshift upstream of the proline-rich regions, which results in insertion of a premature termination codon.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Levels of mRNA expression of ADAM15 isoforms in breast cancer tissues. Expression of ADAM-15A, ADAM-15B, ADAM-15C, and ADAM-15D isoforms was quantified by TaqMan real-time reverse transcription-PCR in 48 breast cancer tissues compared with 10 control normal mammary tissues. Points, mean; bars, SE. Significance was determined by t test.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Relationships between ADAM-15 isoform expression and survival in node-negative and node-positive breast cancer patients. Expression of ADAM-15A, ADAM-15B, and ADAM-15C mRNAs were quantified in a second independent cohort of 229 breast cancer patients, and correlated with clinical outcome. Patients were divided into high (>median) and low (<median) levels of the individual ADAM isoforms. Continuous line, low-level expression; dotted line, high-level expression. X axis, time after surgery in months; Y axis, relapse-free survival in percent (see Materials and Methods).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Characterization of ADAM-15 stably transfected MDA-MB-435 cells. A. Western blot analysis: Cell lysates were blotted with antibodies to the V5 epitope tag and to ADAM-15 as indicated. Representative clones of ADAM15A and ADAM15B that displayed equivalent levels of tagged protein were used for further studies. B. Cell size was determined by counting pixels in the images of 15 to 20 cells in fields chosen at random. C. Immunocytochemical analysis of FAK localization and morphology of the actin cytoskeleton. F-actin (top) was stained with rhodamine-phalloidin; FAK immunostaining (middle) was carried out as described in Materials and Methods. The merged image of FAK and actin staining is shown in the bottom panel. Scale bar, 20 μm.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Cell adhesion, migration, invasion, and metastasis of ADAM-15 stably transfected cells. A. Cell adhesion: 8 × 104 MDA-MB-435 cells were seeded in triplicate in 96-well plates in serum-free medium and incubated for 1 h at 37°C, and then washed well with warm PBS, fixed, and stained with methylene blue; their absorbance was determined at 630 nm. Each clone was tested in triplicate (V, vector control; A, ADAM-15A; B, ADAM-15B). Columns, mean of three independent experiments; bars, SD. B. De-adhesion assay: Growing MDA-MB-435 cells were washed and incubated either in PBS or with EDTA-EGTA for 5 min as in Materials and Methods. The percentage of cells remaining attached were determined as for the adhesion assay (data are the SE values of two clones). C. De-adhesion assay with stably transfected MCF-7 cells: Cells were treated as in B either in PBS or with EDTA-EGTA for 5 min. The percentage of cells remaining attached were determined as for the adhesion assay (data are the SE values of two independent experiments with one clone of each type assayed in triplicate in each experiment.). D. Scratch wound assay: Confluent MDA-MB-435 cells in chamber slides were wounded by scratching using micropipette tips and were incubated with 2% FCS medium for 24 h. Cells migrating into the wound side were counted and data from three experiments were plotted (left); wound closure was also shown (right). Significance was determined by the t test (*P < 0.05, **P < 0.01). E. Matrigel invasion of MDA-MB-435 cells overexpressing ADAM-15 variants. Overexpression of variant A led to a significant induction (99%, P = 0.029) of Matrigel invasion, whereas there was no significant difference between the other groups (mean ± SE, V: 467.3 ± 55.4, n = 4; A: 931.3 ± 173.9, n = 4; B: 658.5 ± 96.7, n = 4). F. Experimental metastasis assay. Significant reduction of the number of X-gal–stained lung colonies by overexpression of ADAM-15A and ADAM-15B variants in MDA-MB-435 cells compared with the vector-transfected control group (V versus A, P = 0.022; V versus B, P = 0.004). Dots, result of one mouse; bar, mean (V: 276 ± 67.23 SE, n = 6; A: 17.33 ± 8.77, n = 6; B: 72.14 ± 19.27, n = 7).

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    ADAM-15 cytoplasmic tail variants selectively associate with signaling molecules. GST-ADAM-15 cytoplasmic domain fusion proteins (ADAM-15A, ADAM-15B, and ADAM-15C) and GST control were used for pull-down assays with lysate from MDA-MB-435 cells (lysate alone shown in the right-hand lane). Bound proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes, followed by Western blotting (WB) using the indicated antibodies. Bottom, Coomassie blue stain for GST fusion protein demonstrating equal loading of the proteins. *, the GST–ADAM-15 tail proteins.

Tables

  • Figures
  • Table 1.

    Categorical Distributions of Baseline Characteristics in All Patients and Associations with ADAM-15 Isoform Expression Levels

    CharacteristicsADAM-15A*
    ADAM-15B*
    ADAM-15C
    <Median>MedianP†<Median>MedianP†<Median>MedianP†
    Age (y)0.1480.6640.991
        ≤5031 (59)22 (41)28 (53)25 (47)26 (49)27 (51)
        >5083 (47)93 (53)87 (49)89 (51)86 (49)89 (51)
    Menopausal status0.2100.2390.881
        Pre33 (57)25 (43)33 (57)25 (43)28 (48)30 (52)
        Post81 (47)90 (53)82 (48)89 (52)84 (49)86 (51)
    Tumor size0.0930.6080.402
        pT129 (47)33 (53)31 (50)31 (50)26 (42)36 (58)
        pT262 (47)71 (53)64 (48)69 (52)67 (51)65 (49)
        pT3+421 (68)10 (32)18 (58)13 (42)17 (55)14 (45)
    Histologic grade0.8280.1740.196
        1/239 (49)41 (53)46 (58)34 (42)39 (49)41 (51)
        341 (53)37 (47)39 (50)39 (50)33 (42)45 (58)
    No. involved lymph nodes0.9560.1940.599
        046 (49)49 (52)45 (47)50 (53)42 (44)53 (56)
        1-335 (51)34 (49)41 (59)28 (41)32 (47)36 (53)
        ≥420 (49)21 (51)18 (44)23 (56)22 (54)19 (46)
    NPI0.3250.1740.977
        13 (43)4 (57)5 (71)2 (29)3 (43)4 (57)
        242 (53)38 (47)51 (64)29 (36)33 (41)47 (59)
        317 (39)27 (61)21 (48)23 (52)19 (43)25 (57)
    ER (fmol/mg protein)0.7430.1230.669
        <1038 (49)40 (51)34 (44)44 (56)39 (51)38 (49)
        ≥1076 (51)73 (49)81 (54)68 (46)71 (48)78 (52)
    PgR (fmol/mg protein)0.8920.8080.174
        <1046 (51)45 (49)45 (49)46 (51)39 (43)51 (57)
        ≥1068 (50)69 (50)70 (51)67 (49)72 (53)65 (47)
    • Abbreviations: NPI, Nottingham Prognostic Index; ER, estrogen receptor; PgR, progesterone receptor.

    • ↵* Number (percentage). Due to missing values, numbers do not always add up to 229.

    • ↵† Pearson χ2.

  • Table 2.

    Cox Regression Survival Analyses for Total ADAM-15A, ADAM-15B, and ADAM-15C Isoforms

    nADAM-15A
    ADAM-15B
    ADAM-15C
    HR (95% CI)PHR (95% CI)PHR (95% CI)P
    All2051.168 (0.758-1.799)0.4811.348 (0.890-2.040)0.1580.775 (0.594-1.011)0.061
    Node-neg952.095 (1.048-4.191)0.0362.923 (1.451-5.888)0.0031.113 (0.616-2.011)0.722
    Node-pos1101.039 (0.504-2.141)0.9181.111 (0.646-1.911)0.7030.703 (0.503-0.984)0.040
    • Abbreviations: HR, hazard ratio; 95% CI, confidence interval.

PreviousNext
Back to top
Molecular Cancer Research: 6 (3)
March 2008
Volume 6, Issue 3
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma
Julia L. Zhong, Zaruhi Poghosyan, Caroline J. Pennington, Xanthe Scott, Madeleine M. Handsley, Alba Warn, Jelena Gavrilovic, Katja Honert, Achim Krüger, Paul N. Span, Fred C.G.J. Sweep and Dylan R. Edwards
Mol Cancer Res March 1 2008 (6) (3) 383-394; DOI: 10.1158/1541-7786.MCR-07-2028

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma
Julia L. Zhong, Zaruhi Poghosyan, Caroline J. Pennington, Xanthe Scott, Madeleine M. Handsley, Alba Warn, Jelena Gavrilovic, Katja Honert, Achim Krüger, Paul N. Span, Fred C.G.J. Sweep and Dylan R. Edwards
Mol Cancer Res March 1 2008 (6) (3) 383-394; DOI: 10.1158/1541-7786.MCR-07-2028
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Breast Stroma Instability
  • PRSS3/Mesotrypsin in Prostate Cancer
  • MUC1 Drives c-Met–Dependent Migration and Scattering
Show more Angiogenesis, Metastasis, and the Cellular Microenvironment
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement